Axsome Therapeutics Scheduled to Report Q3 2026 Earnings
Axsome Therapeutics (AXSM) is set to release its third-quarter 2026 financial results on Monday, November 2nd, prior to the market opening. The company's performance will be measured against significant year-over-year growth expectations in both top and bottom lines. Market analysts have established a consensus EPS estimate of -$0.64, representing a 31.9% improvement compared to the previous year. Revenue is projected to reach $249.19 million, marking a substantial 45.7% increase year-over-year, signaling strong commercial momentum for the biotechnology firm.
Tickers: $AXSM